Aspira Biosystems is developing advanced capture agents and protein biochips for predictable proteomics. Our products are based on a patented platform technology, called ProteinPrint™, which enables sequence-based separation and high-throughput analysis of known and unknown proteins.
Aspira's ProteinPrint technology represents a major breakthrough for the biopharmaceutical industry. Protein research and drug discovery laboratories that have identified proteins of interest using gel electrophoresis, high-throughput gene analyses or database searches can rapidly obtain highly specific capture agents for target validation and high-throughput screening.
Ms. Lynch has a scientific background in disease research, drug discovery and cell biology. Previously, Ms. Lynch has worked at Centaur Pharmaceuticals where she investigated the effect of proprietary small molecules on multiple sclerosis, arthritis, and chemotherapy toxicity. She has also worked in a number of academic and government laboratories investigating the molecular and cellular basis for schizophrenia, epilepsy, and Alzheimer’s disease. Ms. Lynch co-founded Aspira Biosystems after several years of doctoral research at Stanford on protein trafficking and signaling. She received a master’s degree in neuroscience from UCSF and a BS in neuroscience from UCLA.
Dr. Huang co-founded Aspira in 1999 and is the inventor of Aspira's ProteinPrint™ technology. He is actively involved in the development of the ProteinPrint technology and is exploring new directions for use of the technology. Dr. Huang has over 15 years of experience in protein chemistry, molecular biology, and cellular biology. His past research includes glutathione synthesis and metabolism, oxidative stress, and tumor resistance to cisplatin. At Stanford University he studied protein modification and function in the Department of Neurology. Dr. Huang has a PhD in Biochemistry from Cornell University, an MS in Molecular Biology from National Tsing Hua University, and a BS in Pharmacy from Kaohsiung Medical College.
Craig Taylor, of Alloy Ventures, has been an active venture capitalist since 1977. He earned a BS (1972) and an MS (1974) in physics from Brown University, and an MBA from Stanford in 1977. He worked in the Office of Technology Licensing at Stanford from 1975-1977. He is a director at Pharmacyclics, and Lynx Pharmaceuticals, both public companies. He serves on the boards of several private companies including Aspira Biosystems, Chimeric Therapies, Galileo Laboratories, Orquest, and Zyomyx. Mr. Taylor is a member of the Board of Directors of the National Venture Capital Association, and serves on the Board of Advisors of the MIT/Stanford Venture Laboratory and the Stanford Office of Technology Licensing GAP fund.